Clinical Trial

Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-12-14; most recent amendment 2026-07-14.
Trial Details
NCT Number NCT07306624
Lead Sponsor STCube, Inc.
Conditions Non Small Cell Lung Cancer
Enrollment 62 participants
Start Date 2026-01-10
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-16